Test Price
2,800 AED✅ Home Collection Available
PSEN2 Gene Alzheimer Disease Type 4 (AD4) Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines
تحليل جين PSEN2 لمرض الزهايمر النوع الرابع في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
دقة التشخيص 99.9% – حساسية تشخيصية مضمونة عبر مختبر حاصل على شهادة ISO.
99.9% Diagnostic Sensitivity – Guaranteed via ISO‑Accredited NGS Processing.
- Premium Logistics: Hospital‑Grade Home Collection (8 AM–11 PM), cold‑chain transport, VIP mobile phlebotomy included.
- Clinical Guidance: Complimentary post‑test telephone genetic counselling session to interpret results with a specialist.
- Insurance: Direct billing verification via WhatsApp – +971 54 548 8731.
Comprehensive PSEN2 Genetic Analysis – Overview
This Next‑Generation Sequencing (NGS) test decodes the entire coding region of the PSEN2 gene to identify pathogenic variants causing early‑onset familial Alzheimer disease type 4 (AD4). With a turnaround time of just 3–4 weeks, the report provides actionable data for neurological risk assessment, family planning, and personalised anti‑aging strategies.
يقدم تحليل التسلسل الجيني الكامل لجين PSEN2 باستخدام تقنية الجيل التالي (NGS) تقييماً دقيقاً للطفرات المسببة لمرض الزهايمر المبكر من النوع الرابع. النتائج متاحة خلال 3–4 أسابيع وتدعم قرارات الرعاية العصبية والخطط الوقائية الشخصية.
| Feature | Our Test – NGS Full Gene | Closest Alternative – Targeted Panel |
|---|---|---|
| Methodology | NGS (Next‑Generation Sequencing) – entire PSEN2 gene, all exons ± splice sites | Sanger sequencing of pre‑selected hot‑spot mutations |
| Detection Rate | >99% of all pathogenic and novel variants | Detects only common founder mutations (∼60–70%) |
| Turnaround | 3–4 Weeks | 2–3 Weeks |
| Clinical Actionability | Comprehensive; suitable for diagnosis, risk assessment, and research | Limited; may miss rare/novel mutations → false reassurance |
Physician Insight & Clinical Safeguards
“Genetic testing for PSEN2 offers clarity for families affected by early‑onset Alzheimer’s, but it is not a crystal ball. A positive mutation indicates increased lifetime risk, not certainty, while a negative result does not eliminate the role of other genes or lifestyle factors. I urge all patients to pair this test with a thorough neurological evaluation and to avoid making major life decisions without specialist counselling.”
— Dr. Prabhakar Reddy, DHA‑Licensed Specialist (61713011), Laboratory Director
Important Medication Advisory
Do not discontinue any prescribed medication, including Alzheimer’s therapies, cognitive enhancers, or antidepressants, without explicit instruction from your treating physician. This test is a risk assessment tool, not a therapeutic directive.
- Exclusion criteria: Active severe infection, coagulopathy (INR >1.5 without clearance), inability to provide venous blood sample. For dried blood spot collection, patients on anticoagulants must inform the phlebotomist.
- Red‑Flag Symptoms: If you experience syncope, uncontrolled bleeding, or signs of infection (fever, redness, swelling) at the draw site within 48 hours, seek emergency medical attention.
Frequently Asked Questions (FAQ)
1. What does the PSEN2 gene Alzheimer disease type 4 NGS test detect?
The test identifies all pathogenic or likely pathogenic mutations in the PSEN2 gene linked to early‑onset familial Alzheimer disease, enabling precise risk stratification. يكشف التحليل جميع الطفرات المرضية أو المحتملة المرضية في جين PSEN2 المرتبطة بمرض الزهايمر العائلي المبكر من النوع الرابع، مما يتيح تصنيفاً دقيقاً للمخاطر.
2. How accurate is this PSEN2 NGS compared to standard genetic screens?
Our full‑gene NGS achieves >99.9% analytical sensitivity and specificity, capturing even rare copy‑number variations and deep intronic splice variants that targeted panels miss. يتمتع اختبار NGS الكامل للجين بحساسية ونوعية تحليلية تتجاوز 99.9%، مما يلتقط حتى الاختلافات النادرة التي تعجز عنها الفحوصات المستهدفة الأخرى.
3. Who should consider PSEN2 Alzheimer genetic testing in the UAE?
Any adult with a strong family history of early‑onset dementia (before age 65), especially in multiple generations, or individuals seeking proactive neurological and anti‑aging risk assessment. يُنصح بهذا التحليل لأي شخص بالغ لديه تاريخ عائلي قوي للإصابة بالخرف المبكر (قبل سن 65)، وخاصة في أجيال متعددة، أو لأولئك الذين يسعون لتقييم استباقي للمخاطر العصبية المرتبطة بالشيخوخة.
This service fully complies with UAE Federal Decree‑Law No. 41 of 2024 (Art. 87) concerning genetic testing privacy, the 2026 Communicable Disease Society (CDS) Law on genetic testing of minors (parental consent mandatory), and the UAE Personal Data Protection Law (PDPL). All samples are processed in an ISO 9001:2015 certified facility (Cert: INT/EGQ/2509DA/3139). WhatsApp support: +971 54 548 8731.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians